Blog

Novel ways to mitigate the toxicity associated with combination therapy for EGFR-mutant advanced NSCLC – ESMO

ESMO/LinkedIn

Mar 27, 2025, 14:29

Novel ways to mitigate the toxicity associated with combination therapy for EGFR-mutant advanced NSCLC – ESMO

ESMO – European Society for Medical Oncology shared a post on LinkedIn:

“Two studies presented at ELCC25 highlight novel ways to mitigate the toxicity associated with combination therapy for EGFR-mutant advanced NSCLC.

The ETOP AMAZE-lung phase II Clinical Trial sought to provide an alternative to amivantamab plus chemotherapy for patients after progression on osimertinib. Amivantamab, lazertinib and bevacizumab demonstrated modest yet durable efficacy with manageable toxicity.
In the COCOON trial, skin adverse events were significantly reduced using a prophylactic enhanced dermatologic regimen compared with standard dermatologic management following the initiation of first-line amivantamab plus lazertinib.

Julien MAZIERES comments on these findings in the ESMO Daily Reporter.”

Amivantamab Bevacizumab cancer chemotherapy COCOON trial EGFR ESMO ESMODailyReporter ETOP AMAZE European Society for Medical Oncology fight against cancer Global fight against cancer Julien Mazières lazertinib NSCLC OncoDaily Oncology osimertinib

In Memory of Bob Marley: His Battle with Melanoma and the Importance of Early Detection

Who From Oncology is Featured in TIME100 Health 2025?

FDA Announces Aggressive Timeline to Scale 1st AI-Assisted Scientific Review Pilot

The Evolving Therapeutic Revolution in Adult Acute Lymphoblastic Leukemia

Francesco Acerbi and Testicular Cancer: The Defender's Fight and Triumphant Return to Football